NDM-1 inhibitors (CrystalGenomics)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameNDM-1 inhibitors (CrystalGenomics)
Drug Alias NameNew Delhi metallo-beta-lactamase 1 inhibitors (CrystalGenomics)antibiotics (CrystalGenomics/AstraZeneca)
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics
Mechanisms of ActionBeta Lactamase inhibitors
TargetsBeta Lactamase
Therapy Area/IndicationsBacterial Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited KingdomSouth Korea
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCrystalgenomics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCrystalgenomics IncAstrazeneca Plc
Active IndicationsN/A
Inactive IndicationsBacterial Infections

Other Information

ATC CodeN/A
Related LinksN/A